NASDAQ:GTHX - G1 Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding G1 Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $22.09 -1.55 (-6.56 %) (As of 01/24/2020 04:00 PM ET) Add Compare Today's Range$21.77Now: $22.09▼$23.7650-Day Range$22.09MA: $25.98▼$31.0052-Week Range$13.87Now: $22.09▼$41.80Volume322,849 shsAverage Volume236,591 shsMarket Capitalization$830.14 millionP/E RatioN/ADividend YieldN/ABeta2.23 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GTHX Previous Symbol CUSIPN/A CIK1560241 Webhttp://www.g1therapeutics.com/ Phone919-213-9835Debt Debt-to-Equity Ratio0.03 Current Ratio14.28 Quick Ratio14.28Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.65 per share Price / Book2.29Profitability EPS (Most Recent Fiscal Year)($2.56) Net Income$-85,290,000.00 Net MarginsN/A Return on Equity-34.28% Return on Assets-32.40%Miscellaneous Employees84 Outstanding Shares37,580,000Market Cap$830.14 million Next Earnings Date2/27/2020 (Estimated) OptionableOptionable Receive GTHX News and Ratings via Email Sign-up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:GTHX Rates by TradingView G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions What is G1 Therapeutics' stock symbol? G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX." How were G1 Therapeutics' earnings last quarter? G1 Therapeutics Inc (NASDAQ:GTHX) announced its earnings results on Tuesday, November, 5th. The company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($0.87) by $0.01. View G1 Therapeutics' Earnings History. When is G1 Therapeutics' next earnings date? G1 Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for G1 Therapeutics. What price target have analysts set for GTHX? 7 Wall Street analysts have issued 12-month target prices for G1 Therapeutics' stock. Their forecasts range from $45.00 to $82.00. On average, they anticipate G1 Therapeutics' share price to reach $67.17 in the next year. This suggests a possible upside of 204.1% from the stock's current price. View Analyst Price Targets for G1 Therapeutics. What is the consensus analysts' recommendation for G1 Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for G1 Therapeutics. What are Wall Street analysts saying about G1 Therapeutics stock? Here are some recent quotes from research analysts about G1 Therapeutics stock: 1. According to Zacks Investment Research, "G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. " (1/8/2020) 2. HC Wainwright analysts commented, "We base our $72 price target on probability-adjusted revenue forecasts for trilaciclib in first line SCLC, second and third line SCLC, and metastatic TNB cancer plus lerociclib in ER+, HER2- breast cancer and EGFR mutant NSCLC. We use the net present value of our revenue forecast through 2026, apply a 50% and 40% POS for trilaciclib and lerociclib, respectively, a 3x price/sales multiple, and a $2.93/share value for the early stage pipeline that includes trilaciclib and lerociclib in other indications, and G1T48." (9/11/2019) Has G1 Therapeutics been receiving favorable news coverage? News articles about GTHX stock have trended negative recently, InfoTrie reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. G1 Therapeutics earned a media sentiment score of -2.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for G1 Therapeutics. Are investors shorting G1 Therapeutics? G1 Therapeutics saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 4,080,000 shares, a decrease of 13.7% from the December 15th total of 4,730,000 shares. Based on an average daily volume of 333,300 shares, the short-interest ratio is currently 12.2 days. Approximately 13.5% of the shares of the stock are sold short. View G1 Therapeutics' Current Options Chain. Who are some of G1 Therapeutics' key competitors? Some companies that are related to G1 Therapeutics include Ultragenyx Pharmaceutical (RARE), PTC Therapeutics (PTCT), Intercept Pharmaceuticals (ICPT), Taro Pharmaceutical Industries (TARO), Myokardia (MYOK), Blueprint Medicines (BPMC), Zai Lab (ZLAB), Apellis Pharmaceuticals (APLS), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Axsome Therapeutics (AXSM), Emergent Biosolutions (EBS), Genmab A/S (GMAB), Alkermes (ALKS) and Biohaven Pharmaceutical (BHVN). What other stocks do shareholders of G1 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Rite Aid (RAD), OASMIA PHARMACE/ADR (OASM), Sorrento Therapeutics (SRNE), Alibaba Group (BABA), Exelixis (EXEL), Viking Therapeutics (VKTX), Bellicum Pharmaceuticals (BLCM), Corbus Pharmaceuticals (CRBP), Eyepoint Pharmaceuticals (EYPT) and Fate Therapeutics (FATE). Who are G1 Therapeutics' key executives? G1 Therapeutics' management team includes the folowing people: Dr. Mark A. Velleca, CEO, Pres & Director (Age 55)Mr. James Stillman Hanson, Gen. Counsel (Age 47)Mr. Terry L. Murdock, Sr. VP of Devel. Operations (Age 59)Mr. John Demaree, Chief Commercial Officer (Age 52)Ms. Jennifer K. Moses, Chief Financial Officer (Age 44) When did G1 Therapeutics IPO? (GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers. Who are G1 Therapeutics' major shareholders? G1 Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.70%) and Alpine Global Management LLC (0.04%). Company insiders that own G1 Therapeutics stock include Barclay A Phillips, Clay Thorp, Cynthia Schwalm, James S Hanson, Jay Strum, Jennifer K Moses, John Demaree, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View Institutional Ownership Trends for G1 Therapeutics. Which institutional investors are selling G1 Therapeutics stock? GTHX stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. View Insider Buying and Selling for G1 Therapeutics. Which institutional investors are buying G1 Therapeutics stock? GTHX stock was acquired by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. Company insiders that have bought G1 Therapeutics stock in the last two years include Cynthia Schwalm, James S Hanson and John Demaree. View Insider Buying and Selling for G1 Therapeutics. How do I buy shares of G1 Therapeutics? Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is G1 Therapeutics' stock price today? One share of GTHX stock can currently be purchased for approximately $22.09. How big of a company is G1 Therapeutics? G1 Therapeutics has a market capitalization of $830.14 million. The company earns $-85,290,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis. G1 Therapeutics employs 84 workers across the globe.View Additional Information About G1 Therapeutics. What is G1 Therapeutics' official website? The official website for G1 Therapeutics is http://www.g1therapeutics.com/. How can I contact G1 Therapeutics? G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835 or via email at [email protected] MarketBeat Community Rating for G1 Therapeutics (NASDAQ GTHX)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 233 (Vote Outperform)Underperform Votes: 247 (Vote Underperform)Total Votes: 480MarketBeat's community ratings are surveys of what our community members think about G1 Therapeutics and other stocks. Vote "Outperform" if you believe GTHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTHX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/25/2020 by MarketBeat.com StaffFeatured Article: What is Cost of Debt?
